^
Association details:
| Biomarker: | ALK positive + ROS1 positive |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer (ID 1008)
Published date:
11/17/2020
Excerpt:
...ALK and ROS1 positive patients who received lorlatinib post progression on initial therapy...Seventy three percent showed clinical response to therapy with median PFS and OS of 16 months (95% CI 14.0-18.2) and 23 months (95% CI 14.6-31.3)….ALK and ROS1 positive lung cancer...
